Børge Nordestgaard, Denmark
Herlev-Gentofte Hospital Department of Clinical Biochemistry
Presenter of 2 Presentations
Worldwide prevalence of familial hypercholesterolemia: Meta-analyses of 11 million subjects
Session Type
Track 2 - Metabolism of Lipids and Lipoproteins
Date
07.10.2020, Wednesday
Session Time
10:00 - 11:13
Lecture Time
11:03 - 11:13
Background and Aims
Background: Despite the enrichment of familial hypercholesterolemia(FH) in subjects with ischemic heart disease(IHD), premature IHD, and hyperlipidemia, overall prevalence estimates are not available.
Aims: Provide worldwide estimates of FH prevalence in subjects with IHD, premature IHD, and hyperlipidemia compared with individuals in the general population.
Methods
Methods: In this systematic review and meta-analyses, Embase, Pubmed and Web of Science search until June 3, 2019 for peer-reviewed literature and conference abstracts reporting a heterozygous FH prevalence in non-founder populations revealed 104 studies eligible for inclusion.
Results
Results: Estimates of FH prevalence were pooled using random effects meta-analyses and were 0.32%(95%Confidence interval:0.26-0.39%,[corresponding to 1:313]) in 10,921,310 unique individuals in the general population(33,036 FH cases) based on 44 studies, 3.2%(2.2-4.3%,[1:31]) in 84,479 unique subjects with IHD(2,103 FH cases) based on 28 studies, 6.7%(4.9-8.7%,[1:15]) in 31,316 unique subjects with premature IHD(1,471 FH cases) based on 32 studies, and 15.4%(9.6-22.2%,[1:6]) in 27,271 unique subjects with hyperlipidemia(2,107 FH cases) based on 19 studies. Study-differences were investigated using subgroups based on publication year, geography, FH diagnostic criteria, and quality score. Seventeen out of 195 countries(9%) in the world have reported an FH prevalence for the general population, leaving 178(91%) countries in the world with an unknown prevalence.
Conclusions
Conclusion: Compared with 1:313 in individuals in the general population, FH prevalence is 10-fold higher in subjects with IHD, 20-fold higher in subjects with premature IHD, and 50-fold higher in subjects with hyperlipidemia. The prevalence of FH in the general population is unknown in 9 of 10 countries in the world.
[{"name":"Worldwide prevalence of familial hypercholesterolemia: Meta-analyses of 11 million subjects","mode":"playlist","public":true,"info":{"id":1276,"presentation":"Worldwide prevalence of familial hypercholesterolemia: Meta-analyses of 11 million subjects","session":"Cellular lipid trafficking","presenter":"B\u00f8rge Nordestgaard, Denmark","photo":""},"playlist":[{"name":"B\u00f8rge Nordestgaard - EAS20 - 1276 - Worldwide prevalence of familial hypercholesterolemia Meta-analy","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/34\/1276.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/34\/1276.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/34\/878FC2D9.jpg","data":[],"tracks":[]}]}]
{"provider":"CTI","provider_live":0,"type":1,"code":"7E22Xi0o1"}
[session]
[presentation]
[presenter]
Limited sensitivity: scores underestimate risk
Session Type
Track 1 - Advanced clinical seminar
Date
07.10.2020, Wednesday
Session Time
11:30 - 12:00
Lecture Time
11:33 - 11:43
[{"name":"Limited sensitivity: scores underestimate risk","mode":"playlist","public":true,"info":{"id":1462,"presentation":"Limited sensitivity: scores underestimate risk","session":"Risk prediction in primary prevention","presenter":"B\u00f8rge Nordestgaard, Denmark","photo":""},"playlist":[{"name":"B\u00f8rge Nordestgaard - EAS20 - 1462 - Limited sensitivity scores underestimate risk","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/32\/1462.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/32\/1462.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/32\/D79DF2C1.jpg","data":[],"tracks":[]}]}]
{"provider":"CTI","provider_live":0,"type":1,"code":"8E22Xi0rd"}
[session]
[presentation]
[presenter]
